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ARTICLE
Peakwide Mapping on Chromosome 3q13 Identifies the Kalirin
Gene as a Novel Candidate Gene for Coronary Artery Disease
Liyong Wang, Elizabeth R. Hauser, Svati H. Shah, Margaret A. Pericak-Vance,* Carol Haynes,
David Crosslin, Marco Harris II, Sarah Nelson, A. Brent Hale, Christopher B. Granger,
Jonathan L. Haines, Christopher J. H. Jones, David Crossman, David Seo, Simon G. Gregory,
William E. Kraus, Pascal J. Goldschmidt-Clermont, and Jeffery M. Vance*
A susceptibility locus for coronary artery disease (CAD) has been mapped to chromosome 3q13-21 in a linkage study of
early-onset CAD. We completed an association-mapping study across the 1-LOD–unit-down supporting interval, using
two independent white case-control data sets (CATHGEN, initial and validation) to evaluate association under the peak.
Single-nucleotide polymorphisms (SNPs) evenly spaced at 100-kb intervals were screened in the initial data set (Np
). Promising SNPs ( ) were then examined in the validation data set ( ). Significant findings ( ) in468 P ! .1 Np 514 P ! .05
the combined initial and validation data sets were further evaluated in multiple independent data sets, including a family-
based data set ( ), an African American case-control data set ( ), and an additional white control dataNp 2,954 Np 190
set ( ). The association between genotype and aortic atherosclerosis was examined in 145 human aortas. TheNp 255
peakwide survey found evidence of association in SNPs from multiple genes. The strongest associations were found in
three SNPs from the kalirin (KALRN) gene, especially in patients with early-onset CAD ( in the combinedPp .00001–00028
CATHGEN data sets). In-depth investigation of the gene found that an intronic SNP, rs9289231, was associated with
early-onset CAD in all white data sets examined ( ). In the joint analysis of all white early-onset CAD casesP ! .05
( ) and controls ( ), rs9289231 was highly significant ( ), with an odds-ratio estimate of 2.1.Np 332 Np 546 Pp .00008
Furthermore, the risk allele of this SNP was associated with atherosclerosis burden ( ) in 145 human aortas. KALRNPp .03
is a protein with many functions, including the inhibition of inducible nitric oxide synthase and guanine-exchange-
factor activity. KALRN and two other associated genes identified in this study (CDGAP and MYLK) belong to the Rho
GTPase–signaling pathway. Our data suggest the importance of the KALRN gene and the Rho GTPase–signaling pathway
in the pathogenesis of CAD.
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Cardiovascular disease—in particular, coronary artery dis-
ease (CAD)—is the leading cause of death and disability
worldwide.1 Like other complex diseases, the etiology of
CAD is multifactorial. Classic epidemiologic studies have
revealed many risk factors for CAD, including age, sex,
hypertension, dyslipidemia, diabetes mellitus, smoking,
and physical inactivity. However, numerous studies have
repeatedly shown that a positive family history is a robust
predictor of CAD, even after adjustment for all known risk
factors,2–6 which suggests that there is a strong genetic
component underlying this complex disease.
Nine genomewide linkage scans for CAD and myocar-
dial infarction (MI) have been conducted,7–15 including the
GENECARD study.12 However, within the linkage regions
identified in these studies, only the TNFSF4 gene on chro-
mosome 1,16 the VAMP8 gene on chromosome 2,17 and
the ALOX5AP gene on chromosome 1313 have been re-
ported as putative CAD-susceptibility genes.
To increase the genetic effect in the families and to at-
tempt to produce a more homogeneous sample, the GENE-
CARD study focused on siblings with early-onset CAD (MIM
%608901) (males aged !51 years and females aged !56
years). The age cutoff for GENECARD was chosen on the
basis of the estimates of the genetic effect on CAD by
several studies.6 The most significant evidence of linkage
in the GENECARD study was found on chromosome 3q13-
21 (multipoint LOD score 3.5), with a peak near the micro-
satellite marker D3S2460. The 1-LOD–unit-down support-
ing interval is large, extending from 115 Mb to 135 Mb
(National Center for Biotechnology Information [NCBI]
build 35). Using ordered subset analysis methodology, we
found that the linkage evidence for this peak was signif-
icantly increased in families with high high-density li-
poprotein cholesterol levels.18 Recently, in support of this
region’s importance for CAD, Bowden et al.19 also reported
linkage to the same GENECARD peak marker—that is,
D3S2460—for CAD and stroke in the Diabetes Heart Study,
with a similar broad linkage region (multipoint LOD score
2.5).
To fine map the chromosome 3 linkage peak, we con-
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Figure 1. Flow chart of staged study design
ducted a peakwide association mapping study, using SNPs,
in two independent white case-control data sets. Signifi-
cant results were then subsequently tested in additional
data sets.
Material and Methods
Subjects
Several independent data sets were used at different stages of this
study. The Duke Institutional Review Board approved all studies,
and all subjects provided signed informed consent.
CATHGEN data sets (initial, validation, and African American).—
CATHGEN subjects were recruited through the cardiac catheter-
ization laboratories at Duke University Hospital. All subjects un-
dergoing catheterization were offered the opportunity to partic-
ipate in the study. To reduce confounding by population sub-
structure, the initial and validation data sets (each with inde-
pendent cases and controls ascertained sequentially) were com-
posed of whites only, with an additional case-control data set
constructed using all CATHGEN African American subjects.
Alzheimer disease controls.—Subjects for a third white control
data set were collected through an ongoing study of susceptibility
genes for Alzheimer disease (M.A.P.-V., principal investigator) at
the Duke Center for Human Genetics. Individuals in this group
were recruited from community meetings and unrelated family
members (e.g., spouses) of Alzheimer disease–affected families.
All individuals were aged 160 years and were self-reported whites.
GENECARD data set.—The sample collection and study design
of the GENECARD study have been reported.12 In brief, GENE-
CARD samples were collected through a collaborative effort from
investigators affiliated with Duke and five other international
sites. The family-based GENECARD data set was composed of fam-
ilies with at least two affected siblings who met the criteria for
early-onset CAD. The majority (190%) of the GENECARD subjects
were white. Unlike the CATHGEN samples, angiographic data were
not available.
Aorta data set.—Human aortas were collected from heart-trans-
plant donors, and each aorta was graded for atherosclerosis bur-
den as described elsewhere.20 All donors of the aortas used in this
study were white.
Classification Criteria
CATHGEN controls and cases were chosen on the basis of their
extent of CAD, as measured by the CAD index (CADi). CADi is
a numerical summary of coronary angiographic data that incor-
porates the extent and anatomical distribution of coronary dis-
ease.21 CATHGEN cases had a CADi 32, and CATHGEN controls
had an age at catheterization 160 years and no diseased vessels,
documented MI, or interventional cardiac procedures. The CADi
threshold used to determine affection status was chosen a priori
on the basis of a previous study.22 A CADi 32 was equivalent to
having at least one major epicardial vessel with 95% stenosis,
ensuring a highly consistent CAD phenotype. Cases with an age
at onset !56 years for females and !51 years for males were clas-
sified as “young affected,” whereas individuals with an age at
onset 56 years for females and 51 years for males were des-
ignated as “old affected,” following the initial GENECARD cri-
teria. In the old affected group, we wanted to adjust for the higher
baseline extent of CAD. Since there is no study suggesting an
appropriate adjustment for this purpose, we chose the cutoff of
CADi 74, since that represents the highest quartile of CADi in
the patients ascertained at the Duke University Health System
cardiac catheterization laboratories. The age at onset of CAD was
defined as the age of first documented surgical or percutaneous
coronary revascularization procedure, MI, or cardiac catheteriza-
tion meeting the above CADi thresholds. The detailed classifi-
cation criteria for the GENECARD samples were published else-
where.23 In brief, the affected individuals had a CADi event at
age !51 for males and !56 for females. Selected control individuals
with Alzheimer disease had no history of MI, diabetes, stroke, or
peripheral vascular disease, as determined by a detailed question-
naire for medical history. Results of their Modified Mini-Mental
Status exam24 were normal. The aorta samples were assigned case
or control status by evaluation of raised lesions by use of the
Pathobiological Determinants of Atherosclerosis in Youth Study
methodology.25 Samples with a raised lesion score 10 were clas-
sified as cases, and all others were controls.
SNP Genotyping
DNA was extracted from whole blood or tissue (aorta), as de-
scribed elsewhere,26 by the Duke Center for Human Genetics DNA-
BANK. SNP genotyping was performed using the TaqMan Allelic
Discrimination assay. For the purpose of quality control, 1 blank,
2 CEPH-pedigree individuals,27 and 12 quality-control samples
were included for every quadrant of the 384-well plate. The qual-
ity-control samples were used to provide duplicated samples with-
in one quadrant, across quadrants within one plate, and across
plates. Results of the CEPH and quality-control samples were
compared, to identify possible sample-plating errors and geno-
type-calling inconsistencies. Hardy-Weinberg equilibrium (HWE)
testing was performed for all markers. SNPs that showed mis-
matches on quality-control samples or that failed the HWE test
( ) in white controls were reviewed by an independent ge-P ! .05
notyping supervisor for potential genotyping errors. All examined
SNPs were successfully genotyped for 95% of the individuals in
the study. On the basis of 126,000 duplicate genotypes, genotyp-
ing error–rate estimates for SNPs meeting the quality-control
benchmarks were !0.2%.
Study Design
The overall study design is illustrated in figure 1. At first, to screen
the large linkage peak region for association and to minimize
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Table 1. Clinical Characteristics of CATHGEN Data Sets
Characteristic
White Initial Data Set White Validation Data Set African American Data Set
Young
Affected
( )Np 184
Old
Affected
( )Np 167
Control
( )Np 117
Young
Affected
( )Np 148
Old
Affected
( )Np 192
Control
( )Np 174
Young
Affected
( )Np 114
Old
Affected
( )Np 59
Control
( )Np 77
Mean age (in years):
At exam 50.2 (7.6)a 66.1 (10.5)a 69.6 (6.7) 53.9 (9.1)a 68.9 (9.1) 69.8 (6.7) 48.7 (6.5)a 63.8 (10.5)a 69.4 (6.2)
At onset 43.4 (5.9) 60.5 (8.9) NA 44.5 (5.4) 61.6 (8.8) NA 45.2 (5.7) 60 (8.9) NA
Mean CADi 56.3 (21.6)a 72.1 (19.2)a 7.3 (9.9) 61.1 (21.4)a 79.1 (16.1)a 5.4 (9) 50.6 (18.9)a 69.5 (20.3)a 5.7 (9.3)
Mean BMI 31 (6.3)a 29.2 (6.6)a 27.6 (6.3) 30.3 (6.4)a 28.7 (5.6) 28.5 (6) 31.6 (7.3) 29.2 (7.3) 31.8 (7.9)
Ever smoked (%) 73.9a 59.3a 41.0 71.0a 57.8a 39.1 57.9 57.6 46.1
Diabetic (%) 29.4a 32.9a 7.7 35.8a 25.0 19.0 41.2 42.4 46.1
Hypertensive (%) 60.9 73.7 63.3 68.2 70.3 67.2 79.8 88.1a 73.7
Male (%) 79.9a 83.8a 46.2 77.0a 85.4a 40.8 54.4 72.9a 44.7
Hyperlipidemic (%) 73.9a 73.1a 39.3 79.7a 70.3a 51.7 68.4a 69.5a 43.4
NOTE.—Numbers within parentheses are SD. NA p not applicable.
a There were significant differences between cases and controls ( ) within each CATHGEN data set. Analysis of variance was performed by x2 test for categoricalP ! .05
variables and by t test for numeric variables.
genotyping labor and cost, the iterated association methodology
(IAM) of Oliveira et al.26 was used. Briefly, SNPs at an average of
100-kb intervals across the 1-LOD–unit-down region of 3q13-21
were chosen for screening. SNPs were chosen using the software
program SNPSelector.28 If none of these initial SNPs demonstrated
significant association, then the SNP density was increased to 50
kb, then to 25 kb, and so on.
Then, to evaluate the significance of the multiple SNPs used in
the peakwide screening, we applied a staged design. The initial
goal was to identify the highest priority SNPs for follow-up ge-
notyping with all surrounding HapMapII tagging SNPs (Inter-
national HapMap Project). In the first stage, we screened SNPs at
the chosen IAM density in the CATHGEN initial data set. Any
significant SNPs were then tested in the second CATHGEN vali-
dation data set. Since we wished to be inclusive rather than ex-
clusive at this stage, all the SNPs that had nominal P values !.1
in the CATHGEN initial data set were analyzed in the CATHGEN
validation data set. The odds-ratio (OR) estimates for each SNP
between the two data sets were then compared, to identify those
SNPs with the most-consistent association results. Since recent
studies have suggested that analyzing one larger data set has more
power and is more reliable in detecting the true genetic associ-
ation for complex disease than is examining two smaller data sets
separately as replication sets,29,30 joint analysis of the CATHGEN
initial and validation data sets was then performed. SNPs that
had a P value !.05 in this combined CATHGEN data set and that
displayed the same direction of association (i.e., ORs) in both the
initial and validation data sets were considered priority SNPs. Re-
gions flanking the priority SNPs were evaluated with all surround-
ing HapMap tagging SNPs (minor-allele frequency 12%; )2r ! 0.7
in the CATHGEN combined data set.
Finally, the most significant SNPs from these tagging-SNP stud-
ies in the CATHGEN combined data set were further evaluated
in the GENECARD family-based data set, the CATHGEN African
American case-control data set, the Alzheimer white control data
set, and the human aorta data set.
Statistical Analysis
Case-control association was examined using logistic regression
analysis. A simple logistic model was fitted, with adjustment for
sex and age at exam in the overall analysis. Since age at onset is
not applicable for the control individuals, we used age at exam
as a covariable in the statistical model, to adjust for age-related
differences that may impact risk factors measured at the time of
catheterization, as well as disease risk between the case and con-
trol groups. In the subset analysis of early-onset and late-onset
CAD, only sex was included as a covariable. This was necessary
because of the different age distributions in cases and controls
that is inherent in the sample selection. A multivariable logistic-
regression model was also used, which included sex, hypertension
(clinically significant hypertension by history), diabetes mellitus
(previous physician diagnosis), BMI, dyslipidemia (previous diag-
nosis and/or treatment of hypercholesterolemia by a physician),
and smoking history (more than half a pack per day) as covari-
ables. For the human aorta samples, age at harvest was included
in the logistic regression analysis, because we did not preselect
cases and controls on the basis of age. The association in the
presence of linkage (APL)31 test was implemented to evaluate fam-
ily-based association in the GENECARD samples. The Graphical
Overview of Linkage Disequilibrium (GOLD) program32 and Hap-
loview33 were used to assess and display linkage disequilibrium
(LD) between SNPs. To evaluate the interaction between genes
that work in the same biological pathway, we analyzed the most-
significant SNPs from each gene in both the additive and multi-
plicative models, using logistic regression. To evaluate the inde-
pendence of the associated markers, backward stepwise logistic
regression was performed. SAS 9.0 was used for statistical analyses.
Raw P values from each association test were reported in this
study. In place of correcting P values for multiple testing, we re-
lied on the staged design and validation of association in multiple
independent data sets to minimize the possibility of a false-pos-
itive finding (see the “Study Design” section). The Linkage and
Association Modeling in Pedigrees test34 was used to evaluate
whether the linkage signal on chromosome 3q13-21 could be
explained by any of the significant SNPs identified in our study.
Results
Clinical Characteristics of Study Subjects
The CATHGEN initial data set consisted of 117 white con-
trols and 351 cases (184 young affected individuals and
167 old affected individuals). The CATHGEN validation
data set included an additional 174 white controls and
340 cases (148 young affected individuals and 192 old af-
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Figure 2. Association tests of 249 SNPs in the CATHGEN initial data set. Each point represents an association test in the initial data
set on one SNP in all affected (square), young affected (blackened diamond), and old affected (unblackened diamond) subgroups. Genes
containing SNPs with evidence of association ( ) are labeled. The line segment illustrates the approximate location of those genesP ! .05
on chromosome 3. Forty-four SNPs with P values !.1 (log10 P value 11.0) were chosen for validation genotyping (figs. 3 and 4).
fected individuals). The combined CATHGEN data set was
composed of 691 cases (332 young affected individuals and
359 old affected individuals) and 291 controls. The CATH-
GEN African American case-control data set comprised 77
controls and 173 cases (114 young affected individualsand
59 old affected individuals). Because of the small number
of African American cases in the old affected subgroup,
that group was not analyzed for association. The indica-
tions for cardiac catheterization in the CATHGEN control
groups was possible ischemic heart disease (66%), followed
by valvular heart disease (8%), congenital heart disease
(!1%), and other indications (including evaluation for
fatigue, preoperative clearance, and asymptomatic de-
creased ejection fraction). Baseline clinical characteristics
are reported in table 1. As expected, the case groups had
a higher prevalence of traditional CAD risk factors than
did the controls. The Alzheimer disease control data set
was composed of 255 whites, with an average age at ex-
amination of 74 years. The clinical characteristics of the
GENECARD samples were reported elsewhere.12,35 This
data set consisted of 1,101 families, with 2,260 affected
individuals, 603 unaffected individuals, and 91 individ-
uals of unknown status. The human aorta data set was
composed of 35 cases and 110 controls.
IAM SNP Screening in the Initial Data Set
To survey the 1-LOD–unit-down region of the chromo-
some 3q13-21 peak, 249 evenly spaced SNPs were geno-
typed, with an average density of one SNP every 84 kb in
the initial CATHGEN data set. Pairwise LD was estimated,
and most SNPs (190%) were not in high LD ( ) with2r ! 0.7
each other. Evidence of association ( ) was observedP ! .05
for 15 SNPs, with the most significant association at SNP
rs2272486, which resides in the kalirin (KALRN) gene
( .0005) (fig. 2). Since the GENECARD study focusedPp
on early-onset CAD, we divided the analysis into separate
groups of young affected and old affected subjects. In the
analysis of young affected subset, evidence of association
( ) was found for 13 SNPs; 5 of them were also sig-P ! .05
nificant in the overall initial–data set analysis. In the an-
alysis of the old affected subset, evidence of association
( ) was found for 12 SNPs; 8 of them were also sig-P ! .05
nificant in the overall initial–data set analysis (fig. 2).
Evaluation of Association in the Validation Data Set
To evaluate the significance of the multiple SNPs tested
in the initial data set, SNPs that had a nominal P value
!.1 were examined in the CATHGEN validation case-con-
trol data set. Among the 44 SNPs tested at this stage, 28
(64%), 23 (52%), and 27 (61%) of the SNPs displayed the
same direction of OR between the initial and the valida-
tion data sets in the overall, young affected, and old af-
fected analyses, respectively (fig. 3). Among these consis-
tent SNPs, SNPs rs1444768 ( ) in the KALRN genePp .0376
and rs4408834 ( ) in the EST BG483991 were sig-Pp .0186
nificant in the validation data set in the overall analysis.
In the analysis of the young affected cases, three SNPs
(rs7613868, rs13075202, and rs1444768) ( –.0039)Pp .0007
in the KALRN gene and rs4408834 ( ) met thePp .0115
significant level of .05 in the validation data set. None of
the consistent SNPs were significant in the analysis of the
old affected cases in the validation data set alone (data
not shown).
Analysis of the Combined Data Sets
Those SNPs that provided consistent OR estimates between
the initial and validation data sets were tested for asso-
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Figure 3. OR estimates of the 44 selected SNPs in the CATHGEN initial and validation data sets. Each diamond represents one of the
selected 44 SNPs ( ) from the initial peakwide screening on 3q13-21. OR estimates were calculated separately for each SNP in theP ! .1
CATHGEN initial and validation data sets. SNPs and genes that had the same genetic effect direction in the initial and the validation
data sets and had a P value !.05 in the joint analysis of the combined CATHGEN data set are displayed as blackened diamonds and
are labeled. A, All affected subjects. B, Young affected subjects. C, Old affected subjects.
ciation in the combined CATHGEN initial and valida-
tion data sets. In the overall analysis, SNPs rs12485719 in
the arginine-fifty homeobox (ARGFX); rs10934490 in the
Cdc42 GTPase–activating protein (CDGAP); rs1147707
in the follistatinlike 1 (FSTL1); rs7613868, rs13075202,
rs1444768, and rs2272486 in the KALRN gene; rs7641464
in the limbic system–associated membrane protein
(LSAMP); hcv1602689 in the myosin light chain kinase
(MYLK); rs3817040 in the Poly (adenosine diphosphate–
ribose) polymerase family member 9 (PARP9); rs1506024
in the Zinc finger and BTB domain containing 20
(ZBTB20) gene; and rs4408834 in the EST gene BG483991
were associated with CAD risk ( ) (fig. 4).Pp .002–.038
We then analyzed the two subsets (young affected and
old affected) in this combined data set. The strongest as-
sociations in this young affected data set were found
at rs7613868, rs13075202, and rs1444768 ( –Pp .00001
.00028) (fig. 4). All three SNPs reside in the KALRN gene,
with limited LD between them ( ) (fig. 5).2r p 0.29–0.81
In the analysis of the old affected cases, the strongest
associations were found with rs4408834 in BG483991
( ) (fig. 4).Pp .0105
Additional HapMap Tagging SNP Genotyping
Given the fact that the strongest association was found
with SNPs rs7613868, rs13075202, and rs1444768, we ex-
amined additional HapMap tagging SNPs around those
three SNPs. The three highly significant SNPs were located
within a 200-kb stretch of DNA. We extended the region
by 100 kb on each side and identified 38 tagging SNPs in
that 400-kb block. The average density for the 38 SNPs
was 1 SNP every 10 kb. Figure 5 illustrates the association
tests in the combined CATHGEN data set on those tagging
SNPs and the three highly significant SNPs from peakwide
association mapping. The corresponding SNP rs numbers
for the SNP identification numbers used in figure 5 are
listed in table 2. In the overall analysis, eight SNPs dis-
played evidence of association ( ). In the sub-Pp .001–.043
set analysis, nine SNPs were associated with the young
affected subset ( ), and four SNPs werePp .00004–.047
associated with the old affected data set ( ).Pp .011–.045
The strongest associations were found in the subset of
young affected cases—that is, SNP 9 and SNP 12 (raw
and .00008, respectively), which remained sig-Pp .00004
nificant even after correcting for multiple testing of the
38 new SNPs at this stage by Bonferroni correction (cor-
rected ). No SNPs in the overall analysis or theP ! .001
subset analysis of the old affected cases survived this strin-
gent correction. SNPs 9 and 12 also remained significant
after adjusting for known CAD risk factors in the young
affected subset ( and .00002, respectively) (tablePp .0002
2).
The majority of the significant SNPs and the most sig-
nificant SNPs reside in the 5′ end of the KALRN gene. Three
significant SNPs—2, 3, and 4—also mapped to a small
gene—Ropporin (ROPN1)—that resides next to the KALRN
gene (fig. 5). Figure 5 also illustrates the LD structure
among the 38 HapMap tagging SNPs and the three highly
significant SNPs, from peakwide association mapping.
There was no strong LD between them ( ) ex-2r p 0–0.85
cept for the LD between SNPs 7 and 9 ( ). In an2r p 0.99
attempt to evaluate whether the multiple significant sig-
nals in this region are independent of each other, back-
ward stepwise logistic regression analysis was performed.
This analysis found that SNP 12 remained highly signif-
icant ( ), and two other SNPs—22 and 31—werePp .0001
marginally significant ( and .09, respectively), evenPp .07
after taking into account other SNPs and variants in the
model, which suggests that the multiple strong associa-
tions in the KALRN gene region are driven mainly by the
SNPs in the KALRN gene, especially SNP 12. In the com-
bined CATHGEN data set, for SNP 12, we counted 0, 39,
and 245 individuals with the GG, GT, and TT genotypes,
respectively, in controls, and 5, 76, and 246 individuals
with the GG, GT, and TT genotypes, respectively, in young
affected individuals.
Validation in Multiple Additional Data Sets
Since the linkage peak was originally identified in families
with early-onset CAD in GENECARD samples and the
strongest evidence of association in the CATHGEN sam-
ples was found with the young affected cases who have
the same age-at-onset criteria as those included in the
GENECARD study, we further evaluated the association of
the nine significant HapMap tagging SNPs and the three
highly significant SNPs identified from peakwide associa-
tion mapping in multiple additional data sets focusing on
early-onset CAD (table 3). First, we constructed an inde-
pendent set of white controls, using control subjects from
an ongoing Alzheimer disease study. The combined young
affected cases from the CATHGEN initial and validation
data sets were compared with this independent control
set. SNPs 4 (ROPN1), 7, 9, 12, and 14 (KALRN) were sig-
nificant in this analysis ( ). Second, we in-Pp .0030–.0261
vestigated the association of these SNPs in the CATHGEN
African American young affected case-control data set.
SNPs 12 ( ) and 22 ( ) were found to bePp .0323 Pp .0298
associated with young affected cases in the African Amer-
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Figure 4. Joint analysis of the 44 selected SNPs in the combined CATHGEN data set (initial and validation data sets). Each point
represents the association test on one of the selected 44 SNPs ( ) from the initial peakwide screening on 3q13-21. Joint analysesP ! .1
were performed separately for the CATHGEN combined data set in all affected (square), young affected (blackened diamond), and old
affected (unblackened diamond). Genes containing SNPs with evidence of association ( ) in the CATHGEN combined data set areP ! .05
labeled. The line segment illustrates the approximate location of those genes on chromosome 3.
ican data set. Third, we evaluated the SNP associations in
the family-based GENECARD data set and found that SNP
12 was significant in this analysis as well ( ). Fi-Pp .0223
nally, we examined whether any SNP genotypes were as-
sociated with atherosclerosis burden in human aortas. In
this analysis, SNPs 7 ( ) and 12 ( ) werePp .0197 Pp .0339
significant. Therefore, SNP 12, the SNP that seemed to
account for most of the association signal in the KALRN
gene region, was significant in all the data sets we exam-
ined. In addition, the direction of the genetic effect and
allele frequency were highly consistent throughout the
multiple data sets except for African Americans (table 3).
Since the association of SNP 12 (rs9289231) was primar-
ily with patients with early-onset CAD in the multiple data
sets we tested, we evaluated the genetic effect of this SNP
on early-onset CAD, using all white young affected (Np
) and control ( ) subjects, to maximize the pre-332 Np 546
cision of the OR estimate. In this analysis, rs9289231 was
highly significant ( ), with an OR estimate ofPp .00008
2.1. This SNP is estimated to explain 12.1% of early-onset
CAD in the sample of case-control subjects used in this
study. However, we did not observe any statistical evi-
dence suggesting that any association individually ac-
counted for the linkage signal in the GENECARD samples.
Discussion
We found evidence of association with CAD in multiple
genes lying under the 3q13-21 peak, with the KALRN SNP
rs9289231 being the most highly significant in our CATH-
GEN data sets, as well as in multiple independent case-
control data sets and a family-based association data set.
Further, the risk allele of rs9289231 was significantly cor-
related with atherosclerosis burden in human aortas (table
3).
Remarkably, two other genes that display evidence of
association with CAD in the combined CATHGEN initial
and validation data set—that is, CDGAP (rs10934490)
( ) and MYLK (hcv1602689) ( ) (fig. 4)—arePp .038 Pp .006
closely tied to KALRN in the same biological pathway, the
Rho GTPase signal–transduction pathway (fig. 6). We did
not observe evidence of statistical interaction between
SNPs residing in these genes, but our sample size is like-
ly too small for detecting such an interaction. The Rho
GTPase is a family of small G proteins that regulate a wide
range of cellular activity—including cell proliferation/
migration/adhesion, cytoskeletal dynamics, oncogenic
transformation, and inflammatory responses—by stim-
ulating downstream signaling pathway.36–39 Some of the
Rho GTPases, such as RhoA and its downstream effector
Rho-kinase (ROCK), have been indicated in many cardio-
vascular activities.37,40–43 It has been reported that the gua-
nine exchange factor (GEF) domain of KALRN—or unc-73
(KALRN’s homolog in Caenorhabditis elegans)—activates
Rac1 by catalyzing the exchange of guanosine diphos-
phate (GDP) with guanosine triphosphate (GTP).44,45 There
is mounting evidence that Rac1 plays an important role
in the vascular cell signaling through regulation on the
NADPH oxidases and the Rac1-dependent production of
reactive oxygen species.46–48
The highly associated SNP rs9289231 resides in the first
intron of an alternative transcript of the KALRN gene (fig.
5). The KALRN gene was originally identified through its
interaction with peptidylglyine a-amidating monooxygen-
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Figure 5. HapMap tagging SNPs in the KALRN gene region. Thirty-eight HapMap tagging SNPs in the KALRN gene region plus the
three significant SNPs from the peakwide survey are displayed (A). The locations of the SNPs are indicated by the arrows with numbers
(1–41). The gene structure is shown in genomic context, with the CCDC14 and ROPN1 genes on the reverse strand and the KALRN gene
on the forward strand. Exons and introns are depicted as dark cylinders and solid lines, respectively. Alternative exons and introns are
depicted as light cylinders and dotted lines, respectively. log10 P values for association test are displayed on a bar graph (B).
Association tests were performed separately for the combined CATHGEN data sets in all affected (white bar), young affected (gray bar),
and old affected (black bar) cases. The three significant SNPs identified from peakwide screening are SNPs 7, 14, and 20 (labeled with
a star). Pairwise r2 was estimated in the controls and is displayed by gray-shaded square with the hundredths of r2 value inside
(HaploView)33 (C). The shades of gray are proportional to the r2 values, with the darkest gray being the highest r2 value. Similar LD
relationships were seen in the affected individuals and are not shown.
ase (PAM) with use of a rat hippocampal cDNA library.49
PAM catalyzes amidation of peptide, a key step in synthe-
sizing bioactive peptides such as neuropeptides and hor-
mones. The KALRN gene encodes many transcript isoforms
through alternative promoters, different internal tran-
scription start sites, and alternative splicing at the 3′
end.50,51 The largest isoform is 11 kb in size and consists
of 60 exons.51 Full-length KALRN possesses multiple func-
tional protein domains, including an Sec14p domain, nine
spectrinlike repeats, two GEF domains, two src homology
3 (SH3) domains, two pleckstrin-homology (PH) domains,
and a putative Ser/Thr protein kinase domain.52 It has been
documented that KALRN interacts with PAM, Huntington-
associated protein 1 (HAP1), and inducible nitric oxide
synthase (iNOS) through the spectrinlike repeats.49,53,54 On
binding to iNOS, KALRN inhibits iNOS activity via pre-
vention of homodimerization of the enzyme.54 Given
the observed cardiovascular activity of nitric oxide,55,56
one possible mechanism for CAD susceptibility involving
KALRN could be through its interaction with iNOS.
It is worth pointing out that our association studies pro-
vide appealing but not definitive evidence that KALRN is
the CAD susceptibility gene, since other genes lie in the
association region. The KALRN gene was identified through
an unbiased association mapping based on SNPs. It is pos-
sible that rs9289231 is a proxy for the causative variant
that is in a high degree of LD with it. According to HapMap
phase II data (International HapMap Project), 10 SNPs are
tagged by rs9289231. Each one of them has the potential
to be the real variant that confers genetic risk for CAD.
Of the 10 SNPs, 8 are located within the KALRN exon
boundaries and upstream promoter region, with 2 mapped
to the adjacent CCDC14 and ROPN1 genes. Without fur-
ther analysis including functional evaluation of these
SNPs, we cannot rule out the possibility that the CCDC14
and ROPN1 genes are the genes driving the observed as-
sociation. However, several points argue against it: (1) the
KALRN gene has known functions that provide a plausible
biological mechanism for its role in atherosclerosis path-
ogenesis, (2) KALRN and the other significant genes iden-
tified in this study—MYLK and CDGAP—share a common
Rho GTPase–signaling pathway, suggesting a potential in-
teracting pathway for CAD pathophysiology, and (3) the
majority of the associated SNPs reside in the KALRN gene.
Interestingly, the ROPN1 gene was initially identified as
an interacting protein with the protein Rhophilin, which
binds specifically to the active form of Rho GTPase.57,58
Therefore, it is also possible that both ROPN1 and KALRN
contribute to the CAD susceptibility through the Rho
GTPase–signaling pathway.
One of the most discussed questions in association stud-
ies is how to evaluate the significance of multiple test-
ing of SNPs. To this end, different methods have been
proposed, including Bonferroni correction, correction by
false-discovery rate, and replication in a second data set.
Recent data generated from the Genetic Analysis Work-
shop 14 found that a multiple-testing correction is usually
too conservative, whereas replication of a nominal P value
in a second data set is less stringent.29 On the other hand,
analysis of markers in one large data set seems to be the
most effective approach in identification of the true-pos-
itive signals.29 Therefore, we applied a staged design en-
hanced by joint analysis in the combined data sets in our
peakwide association mapping. In addition, we sought to
validate the most promising associations in multiple in-
dependent data sets, to filter out the false-positive asso-
ciation. However, it is worth noting that the strong as-
sociation in the KALRN gene region would survive all of
these methods for multiple-testing corrections.
Another major concern in a case-control association
study is the fact that population stratification could lead
to false-positive findings. The strength of our study re-
lies on the validation of association in multiple indepen-
dent data sets, including a family-based data set, which
is more robust against population stratification than the
case-control design. Therefore, although we cannot ex-
clude the possibility, it is unlikely that the consistent as-
sociation reported here was caused by population strati-
fication. Constrained by the available clinical data, the
cases were defined by somewhat different but well-ac-
cepted criteria for CAD between data sets. The variation
in case definition could potentially diminish the evidence
of association and lead to false-negative results because of
heterogeneity. The fact that we observed associations in
all early-onset CAD groups suggests that the genetic effect
is indeed robust. Our data merit studies of additional data
sets, to further validate this novel finding. Given that the
strongest genetic effect was seen in the subset of patients
with early-onset CAD, future association studies should
focus on early-onset CAD. Since we do not have definitive
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Table 2. Association of the HapMap Tagging SNPs in the KALRN Gene Region in the Young Affected Subset
of the Combined CATHGEN Data Sets
SNP Identification
Base-Pair
Location Locus Allele
Allele Frequency
(%) Association Test P (OR)
Young
Affected
np 332
Control
np 291 Basic Model Full Model
rs6766344 1 125110476 CCDC14 A 5 7 .2442 (.7) .3929 (.8)
rs6810298 2 125177665 ROPN1 G 34 27 .0082 (1.4) .0064 (1.5)
rs17376453 3 125179139 ROPN1 C 18 12 .017 (1.5) .0094 (1.7)
rs7434266 4 125188532 ROPN1 A 23 16 .002 (1.6) .0027 (1.7)
rs7429448 5 125198542 ROPN1 A 12 9 .2459 (1.3) .512 (1.2)
rs9813249 6 125215401 KALRN C 9 7 .1691 (1.4) .3344 (1.3)
rs7613868 7 125224719 KALRN A 35 24 1#1055 (1.9) 7#1055 (1.9)
rs12634530 8 125227160 KALRN T 21 16 .0474 (1.4) .3313 (1.2)
rs12637456 9 125227353 KALRN A 35 24 4#1055- (1.8) .0002 (1.8)
rs869585 10 125236654 KALRN A 3 1 .2468 (1.8) .2546 (1.9)
rs2332690 11 125250612 KALRN A 18 15 .1396 (1.3) .4009 (1.2)
rs9289231 12 125256768 KALRN G 13 7 8#1055 (2.4) 2#1055 (3.0)
rs16835038 13 125259296 KALRN G 5 5 .5086 (.8) .428 (.8)
rs13075202 14 125304977 KALRN G 30 21 .0003 (1.7) .0004 (1.8)
rs11714061 15 125308212 KALRN A 11 9 .4785 (1.2) .4537 (1.2)
rs1316375 16 125316304 KALRN A 10 8 .7958 (1.1) .5739 (1.2)
rs16835137 17 125368709 KALRN A 8 7 .7951 (1.1) .8193 (1.1)
rs16835162 18 125386881 KALRN G 16 15 .7869 (1.0) .738 (1.1)
rs7627053 19 125404954 KALRN A 7 6 .3573 (1.3) .3955 (1.3)
rs1444768 20 125406612 KALRN G 41 29 8#1055 (1.7) .0002 (1.8)
rs1444767 21 125407493 KALRN T 10 8 .2524 (1.3) .4137 (1.2)
rs1444754 22 125420907 KALRN C 43 34 .0042 (1.4) .0217 (1.4)
rs9833095 23 125430323 KALRN A 5 4 .369 (1.3) .6735 (1.1)
rs13066449 24 125433827 KALRN T 40 36 .2095 (1.2) .1442 (1.2)
rs1920629 25 125435293 KALRN T 4 4 .9869 (1.0) .5881 (.8)
rs4678095 26 125439286 KALRN C 49 55 .0818 (.8) .1155 (.8)
rs1158012 27 125440085 KALRN T 45 51 .0824 (.8) .3365 (.9)
rs11720960 28 125440632 KALRN C 7 8 .2536 (.8) .3849 (.8)
rs7616435 29 125442275 KALRN G 7 5 .0835 (1.6) .1392 (1.5)
rs4678097 30 125443420 KALRN G 17 16 .6955 (1.1) .9644 (1.0)
rs4234218 31 125443900 KALRN G 41 33 .0067 (1.4) .044 (1.3)
rs6794049 32 125444174 KALRN T 2 3 .1567 (.5) .2525 (.6)
rs4608635 33 125444186 KALRN C 34 38 .2281 (.9) .5178 (.9)
rs4678100 34 125452115 KALRN C 8 5 .0771 (1.5) .3252 (1.3)
rs6438837 35 125453375 KALRN G 10 12 .2864 (.8) .5601 (.9)
rs17221479 36 125460168 KALRN T 10 9 .9454 (1.0) .6881 (.9)
rs11929003 37 125462011 KALRN G 45 50 .0364 (.8) .1839 (.8)
rs9813731 38 125468728 KALRN G 5 3 .098 (1.7) .3906 (1.4)
rs9868324 39 125472134 KALRN A 20 21 .5441 (.9) .6839 (.9)
rs2332769 40 125485918 KALRN A 35 40 .0982 (.8) .3415 (.9)
rs1444746 41 125494623 KALRN C 42 47 .181 (.8) .3987 (.9)
NOTE.—The physical location of each SNP is based on NCBI build 35. Genotype-based association tests were performed in the
young affected cases versus controls in the combined CATHGEN data sets, with adjustment for sex (basic model) or adjustment for
sex, hypertension, diabetes mellitus, BMI, dyslipidemia, and smoking history (full model). P values !.05 are shown in bold.
evidence suggesting that rs9289231 is the causative SNP,
it is important that future studies test all the significant
SNPs in the KALRN gene region that are not in high LD
( ), as well as the significant SNPs in the CDGAP and2r ! 0.7
MYLK genes.
The finding of multiple associated genes under one large
linkage peak for a complex trait, as seen in the present
study, is interesting. The genetic basis for a common com-
plex disease like CAD is believed to be polygenic and
highly heterogeneous. The observed variability of disease
phenotype is likely the contribution from many genes. It
is quite possible that the presence of multiple susceptibility
genes in the same region makes the region more likely to
be detected in the linkage study. Interestingly, despite the
multiple associations identified for 3q13-21, we did not
find statistical evidence suggesting that any single SNP ac-
counts for a significant amount of linkage signal in 3q13-
21. One possible explanation for this discrepancy is that
the observed linkage comes from the contribution of mul-
tiple loci and, therefore, no single locus can reach statis-
tical significance. Alternatively, it is still possible that we
missed the genetic variants that are responsible for the
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Figure 6. Illustration of key proteins in the Rho GTPase signal–
transduction pathway, focusing on the KALRN, CDGAP, and MYLK
genes. The Rho GTPase signal–transduction pathway focusing on
the three associated genes on chromosome 3q13-21—KALRN, CDGAP,
and MYLK—is illustrated. Displayed P values are the smallest P
value for each gene from the joint analysis of the combined CATH-
GEN initial and validation data sets.
linkage signal, because of incomplete coverage of genetic
contents in the region. Future studies, including deep re-
sequencing studies, are needed to catalog all the genetic
variations in this important region that have accumulated
several lines of evidence of CAD risk.
In summary, we conducted a peakwide association map-
ping on 3q13-21 and identified multiple candidate genes
for CAD susceptibility. The association with CAD in the
KALRN gene was the strongest in this analysis and was
validated in multiple data sets with different study designs
and disease models. The association with the KALRN gene
was significant even after adjustment for most known CAD
risk factors, suggesting that the genetic effect is robust and
confers susceptibility beyond that confirmed by known
risk factors. In addition, two genes with positive associa-
tion (CDGAP and MYLK) identified in this study belong
to the same biological pathway; this suggests the impor-
tance of the Rho GTPase signal–transduction pathway in
the pathogenesis of CAD and merits further study.
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